Parkinson's disease patient, what treatment did you enjoy in badminton a year later?
Nov 13, 2024
A year after administration of a mesencephalon dopamine nerve cell therapy derived from embryonic stem cells, it was effective in patients with Parkinson's disease.
A clinical research team led by Professor Lee Pil-Hue of the Department of Neurology at Severance Hospital and Professor Jang Jin-Woo of Neurology at Korea University Anam Hospital announced that 12 Parkinson's disease patients showed improvement in symptoms a year after transplantation in low and high doses, respectively.
Parkinson's patients, who started playing badminton and table tennis a year after administration and became more convenient in their daily lives, showed side effects such as drug use exhaustion or walking freezing, which reduced drug effectiveness even after receiving dopamine drug treatment.
Severance Hospital plans to follow up and observe the progress for up to two years after transplantation according to the clinical trial plan. Regarding safety, 1 out of 12 transplanted patients to date had mild bleeding in the surrounding areas unrelated to the transplant site, but there were no unusual neurological abnormalities or side effects. In addition, no unusual side effects associated with cell transplantation were observed in all patients.
The research team measured the degree of improvement in symptoms in three patient groups, one year after the administration of low doses (3.15 million cells) and high doses (6.3 million cells) among 12 subjects.
On the Hoenya scale, which divided Parkinson's disease symptoms into stages 1 to 5 by increasing them according to their severity, an average of 19.4% (3.7 stages → 3 stages) improved for low-dose administrators. In high-dose administrators, an average of 44.4% (step 3.7 → step 2) improved. The degree of improvement in the high dose means improvement from a severe state to an initial state of the disease.
On the Parkinson's evaluation scale, which evaluates objective exercise performance and increases scores when severe, low-dose administrators improved 22.7% (reduced 12.7 points) and high-dose administrators improved 25.3% (13 points).
The side effects of freezing walking, which temporarily stops moving when walking or changing directions, disappeared in one out of two low-dose administrators (50% improvement), and all disappeared in three high-dose administrators (100% improvement), indicating a recovery to normal.
For some administrators, Parkinson's assessment scale improved significantly to 40.7% after 1 year (22 points decreased), suggesting the potential of this treatment as a game changer in the treatment of Parkinson's disease.
Even when dopamine brain images were taken, it could be observed that the dopamine-secreting dopamine cell incidence signal was increased, and the signal increase was large at a high dose. The increase in the signal of this brain image showed a direct association with patient efficacy indicators that showed effectiveness as evidence of the treatment mechanism. Dopamine is a substance that helps people move smoothly and is secreted less in Parkinson's disease patients.
Professor Kim Dong-wook of the Department of Physiology at Yonsei University School of Medicine, the developer of the treatment, said, "The cell therapy we developed utilized human embryonic stem cells and reduced the typical side effects such as walking freeze and drug use."As patients who have had Parkinson's disease for a long time now enjoy badminton and walking after administration, fundamental treatments will contribute to helping patients regain a healthy life." S Biomedics Co., Ltd. is in charge of manufacturing and supplying Parkinson's disease cell therapy.
A clinical research team led by Professor Lee Pil-Hue of the Department of Neurology at Severance Hospital and Professor Jang Jin-Woo of Neurology at Korea University Anam Hospital announced that 12 Parkinson's disease patients showed improvement in symptoms a year after transplantation in low and high doses, respectively.
Parkinson's patients, who started playing badminton and table tennis a year after administration and became more convenient in their daily lives, showed side effects such as drug use exhaustion or walking freezing, which reduced drug effectiveness even after receiving dopamine drug treatment.
Severance Hospital plans to follow up and observe the progress for up to two years after transplantation according to the clinical trial plan. Regarding safety, 1 out of 12 transplanted patients to date had mild bleeding in the surrounding areas unrelated to the transplant site, but there were no unusual neurological abnormalities or side effects. In addition, no unusual side effects associated with cell transplantation were observed in all patients.
The research team measured the degree of improvement in symptoms in three patient groups, one year after the administration of low doses (3.15 million cells) and high doses (6.3 million cells) among 12 subjects.
On the Hoenya scale, which divided Parkinson's disease symptoms into stages 1 to 5 by increasing them according to their severity, an average of 19.4% (3.7 stages → 3 stages) improved for low-dose administrators. In high-dose administrators, an average of 44.4% (step 3.7 → step 2) improved. The degree of improvement in the high dose means improvement from a severe state to an initial state of the disease.
On the Parkinson's evaluation scale, which evaluates objective exercise performance and increases scores when severe, low-dose administrators improved 22.7% (reduced 12.7 points) and high-dose administrators improved 25.3% (13 points).
The side effects of freezing walking, which temporarily stops moving when walking or changing directions, disappeared in one out of two low-dose administrators (50% improvement), and all disappeared in three high-dose administrators (100% improvement), indicating a recovery to normal.
For some administrators, Parkinson's assessment scale improved significantly to 40.7% after 1 year (22 points decreased), suggesting the potential of this treatment as a game changer in the treatment of Parkinson's disease.
Even when dopamine brain images were taken, it could be observed that the dopamine-secreting dopamine cell incidence signal was increased, and the signal increase was large at a high dose. The increase in the signal of this brain image showed a direct association with patient efficacy indicators that showed effectiveness as evidence of the treatment mechanism. Dopamine is a substance that helps people move smoothly and is secreted less in Parkinson's disease patients.
Professor Kim Dong-wook of the Department of Physiology at Yonsei University School of Medicine, the developer of the treatment, said, "The cell therapy we developed utilized human embryonic stem cells and reduced the typical side effects such as walking freeze and drug use."As patients who have had Parkinson's disease for a long time now enjoy badminton and walking after administration, fundamental treatments will contribute to helping patients regain a healthy life." S Biomedics Co., Ltd. is in charge of manufacturing and supplying Parkinson's disease cell therapy.
|
bellho@sportschosun.com
